Skip to content

Deliver Direct-to-Participant

Opportunity

It is important to consider how study participants receive their study medication, to minimize impact to their time / effort and to align with a move towards decentralization of clinical trials. The provision of study medication could be achieved through direct-to-participant (otherwise known as direct-to-patient (DtP)) shipping, which includes depot-to-patient, pharmacy-to-patient, clinical site-to-patient, or by shipping to a local pharmacy or clinic for collection.

Considerations to Help Action the Opportunity

  • Understand patients’ preference and capabilities for receipt of study medication (i.e., shipment to home vs collection from local clinic / pharmacy)
  • Develop training and documentation to facilitate participant / care partner(s) use and confident compliance; emphasize site contacts or other contacts for questions or support
  • Understand whether the study medication is appropriate for at home administration / storage; detailed risk assessment may be appropriate
  • Understand the distribution models in each country to manage the full chain of custody that satisfies regulatory and privacy requirements, given that these requirements for DtP are generally country-specific 
  • Partner with sites to support acceptance of study medication transport from site pharmacy, or depot, and according to site processes
  • Understand site challenges / concerns associated with third-party and participant oversight and their ability to maintain study drug oversight
  • Understand the requirements of the site pharmacy, depot or local clinic / pharmacy to prepare study medication for transport, at home storage and use
  • Define appropriate storage facilities and controls to maintain stability, prevent temperature excursions or unauthorized use at participants’ home
  • Define how unused medication will be returned and the systems and processes needed to manage accountability and compliance (e.g., IXRS, EDC)
  • Develop medication compliance measures to accommodate for the change in oversight
  • Partner with vendors to cover critical services needed to address study medication stability and confirmation of delivery to participant is obtained
  • Evaluate shipping vendors qualifications for study medicine shipment, as per local requirements for dispensing and cross-border / state transport

Value and Potential Benefits

  • Helps to improve patient recruitment and retention by reducing the number of in clinic visits (e.g., to collect and / or re-supply study medication) and subsequent impact on participants daily life, potentially leading to increased participant interest to join a clinical trial

Related Blog Posts

A New Era in Advancing Care for Pregnant and Breastfeeding Patients

One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations  (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…

Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward   

The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…

Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges

Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…